Lentiviral Transduction Protocol: Packaging, Titering, MOI, and Biosafety

Lentiviral transduction uses a replication-incompetent viral vector, derived from HIV-1, to deliver genetic material into cells. It is a form of transduction, not transfection — the two terms are often used interchangeably in casual lab speech, but they describe different delivery mechanisms with different biosafety obligations. For the chemical/physical, non-viral methods (lipofection, calcium phosphate, PEI, electroporation) and how to choose between them, see Transfection: Choosing a Method, Optimising It, and the Biosafety Approval You Need, which also covers electroporation in depth. This guide covers the viral-vector side specifically: lentivirus, its production and titering workflow, transduction mechanics, and the compliance layer that applies before any of it can start.

Why lentivirus, specifically

Lentivirus belongs to the retrovirus family but, unlike a standard (gamma-)retroviral vector, it can cross an intact nuclear envelope. That single property is what makes it useful across a much wider range of experiments:

• It transduces both dividing and non-dividing cells. Gamma-retroviral vectors require the nuclear envelope to break down during mitosis to integrate, which excludes most primary, post-mitotic, and terminally differentiated cell types (neurons, macrophages, resting T cells). Lentivirus does not have that restriction.
• It integrates stably into the host genome. The provirus is inherited by daughter cells, which is what makes lentivirus the standard choice for stable overexpression, stable knockdown (shRNA), CRISPR component delivery into hard-to-transfect lines, and generating stable reporter or CAR-expressing cell lines — anywhere a transient signal (as from lipofection or electroporation) is not enough.
• It has a moderate cargo capacity (roughly 8–10 kb of insert, vector-dependent) — larger than AAV, though AAV is often preferred for in vivo work specifically because it is largely non-integrating and less immunogenic.

The trade-off is the one this guide spends real space on: stable genomic integration and a viral envelope both raise the biosafety and institutional-approval bar well above what a chemical transfection requires.

The production and transduction workflow

1. Vector design and the packaging system

A modern lentiviral system is deliberately split across multiple plasmids so that no single piece of DNA carries enough of the viral genome to reconstitute a replication-competent virus if it were ever recombined back together. Two generations are in common current use:

• Second-generation, 3-plasmid systems — a packaging plasmid providing gag/pol (and often rev), an envelope plasmid (commonly pMD2.G, providing the VSV-G envelope glycoprotein that gives lentivirus its broad tropism), and the transfer plasmid carrying your gene of interest between the viral LTRs.
• Third-generation, 4-plasmid systems — split further (e.g. psPAX2-style gag/pol, a separate rev plasmid, pMD2.G for envelope, plus the transfer plasmid) and, critically, remove the HIV tat gene from the packaging components, requiring only three of the original nine HIV genes to be reconstituted for any risk of replication competence. Third-generation, self-inactivating (SIN) transfer vectors — with a deleted U3 region in the 3′ LTR that disables the LTR promoter after integration — are now the standard default precisely because they reduce insertional-mutagenesis and replication-competent-lentivirus (RCL) risk relative to earlier designs.

Producer cells are transiently co-transfected with the plasmid set (HEK293T is the standard producer line, chosen for high transfectability and efficient viral protein production) using a lipid- or PEI-based transfection reagent — the production step is itself a transfection, even though the end product is a transducing viral particle.

2. Harvest and concentration

Supernatant is collected 24–72 hours post-transfection (often pooled across two collection windows), cleared of cell debris by low-speed centrifugation or 0.45 μm filtration, and used directly or concentrated (ultracentrifugation, PEG precipitation, or a commercial concentration column) when a higher-titer stock is needed than crude supernatant provides.

3. Titering

You cannot set a meaningful MOI without knowing your actual functional titer — the number of transducing units per mL, not the physical particle count, which overstates infectivity because it includes non-functional and empty particles. The common approach: transduce a permissive reporter line with a dilution series of the viral stock, then read out the fraction of positive cells a few days later (flow cytometry for a fluorescent transfer construct — see how flow cytometry works — or colony counts under selection for a resistance-marker construct) and back-calculate transducing units/mL from the dilution that gives a countable, sub-saturating percentage of positive cells. qPCR-based titering (against integrated provirus or vector genomes) is the other common method and is generally required for clinical-grade or GMP vector lots.

4. The transduction step

Target cells are seeded at a defined, recorded confluency (the same under-controlled variable that drives efficiency swings in chemical transfection — see the confluency discussion in the transfection guide linked above), then exposed to virus at the calculated volume for your target MOI. Polybrene (hexadimethrine bromide, typically used around 6–8 μg/mL) is the standard transduction enhancer: it is a cationic polymer that neutralizes the charge repulsion between the negatively charged viral envelope and cell surface, increasing effective contact and transduction efficiency. Polybrene is toxic to some sensitive and primary cell types at standard concentrations, so it is worth titrating down (or substituting an alternative enhancer, or using spinoculation — centrifuging the plate during virus exposure) rather than assuming the default concentration is safe for every line. Retronectin-coated plates are a common polybrene-free alternative, particularly for sensitive hematopoietic and primary cell work.

5. MOI: the key optimization variable

Multiplicity of infection (MOI) is the ratio of transducing viral particles added per target cell. It is the single most consequential parameter to get right:

• Too low, and too few cells integrate the construct, requiring a longer or harsher selection to isolate a usable population, or leaving too few transduced cells for downstream work.
• Too high, and cells increasingly acquire multiple integration events. For overexpression or reporter work that can be tolerable or even desirable; for anything where copy number matters — a CRISPR knockout or knock-in line intended to model a single-copy genetic change, a shRNA line where dose-dependent off-target effects are a concern — multiple integrations per cell confound the result and are usually the opposite of what you want. High MOI also increases both cytotoxicity from viral load itself and the (still-rare, but non-zero) probability of recombination events.

The correct practice is to run a small MOI titration (e.g. 0.1, 0.5, 1, 5, 10) on the actual target cell line for the actual construct, not to inherit a number from an unrelated paper or vendor protocol — efficiency and tolerance both vary substantially by cell type, exactly as with chemical transfection. Many stable-line workflows deliberately target a low MOI (well under 1) specifically to bias toward single-copy integration per cell, accepting a lower initial transduction rate in exchange for a cleaner, more interpretable line.

6. Selecting transduced cells

Because integration is stable, selection is usually straightforward once transduction efficiency is known:

• Antibiotic resistance — puromycin, blasticidin, hygromycin, and neomycin/G418 resistance cassettes are all common on lentiviral transfer plasmids. Establish the antibiotic kill curve on your specific, untransduced line first (a concentration and timeline borrowed from a different line is a common source of a failed selection), then select for one to two weeks until untransduced control wells are fully cleared.
• Fluorescent marker sorting — GFP, mCherry, or similar reporters (often on the same construct as the gene of interest, via an IRES or self-cleaving 2A peptide) let you isolate transduced cells directly by fluorescence-activated cell sorting rather than by chemical selection, which is faster and avoids selection-drug side effects, at the cost of needing sorter access.

Whichever method is used, confirm the resulting population by an independent readout (expression by western blot or qPCR, functional knockdown/knockout confirmation) rather than assuming resistance or fluorescence alone proves the intended genetic change is present and functional.

Biosafety and institutional approval

This is the part a vendor’s bench protocol will not walk you through, and it is not optional. Lentiviral vectors are derived from HIV-1, and even though modern third-generation, SIN, replication-incompetent designs are engineered specifically to minimize replication-competent-lentivirus risk, that risk assessment is an institutional one, not a bench decision.

• Institutional Biosafety Committee (IBC) review and approval is required before work begins for essentially all recombinant/synthetic nucleic acid research at institutions receiving NIH funding, under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules — see the Institutional Biosafety Committee entry and the fuller IBC guide. Starting lentiviral work without that approval in place is a reportable non-compliance, not a paperwork formality to catch up on later — and because IBCs meet on a committee cycle rather than continuously, budget weeks into a project timeline, not days.
• Lentiviral work is commonly assigned Biosafety Level 2 (BSL-2) or BSL-2 with enhanced practices — see BSL-2 — with the exact tier depending on the vector generation, whether it is VSV-G pseudotyped (which broadens tropism to human cells, a factor in the risk assessment), and what the insert itself encodes. An insert carrying an oncogene, a toxin, or anything that could plausibly alter host range or pathogenicity raises the risk assessment independent of the vector backbone, the same way it does for non-viral transfection of the equivalent insert.
• Occupational health and exposure planning typically apply: needlestick or sharps exposure during viral work is treated as a real exposure event with a defined response pathway, and some institutions require baseline or ongoing health surveillance for personnel doing regular lentiviral work.
• Engineering and procedural controls commonly required at BSL-2 for aerosol-generating steps — vortexing, centrifuging open tubes of viral supernatant, needle use — include performing those steps inside a certified biosafety cabinet, using aerosol-tight rotor lids for centrifugation, and decontaminating waste (typically with a validated disinfectant effective against enveloped viruses, e.g. an appropriate-contact-time bleach solution) before disposal.
• Training and documentation — expect a requirement for documented biosafety training specific to viral vector work, a written, IBC-approved protocol, and inventory/tracking records for the vector stock itself.

Confirm your institution’s specific containment tier, waste-decontamination procedure, and any additional local requirements with your biosafety office before starting — these vary by institution and by the specific construct, and this guide describes the general framework, not a substitute for that review.

Troubleshooting by symptom

Low transduction efficiency

Re-titer your viral stock rather than trusting an old titer — lentivirus loses activity on freeze-thaw and during storage, and a stock titered months ago may no longer reflect its current functional titer. Confirm target-cell confluency and health, check that polybrene (or an alternative enhancer) was actually included, and verify the transfer plasmid map and insert by sequencing rather than assuming the packaged construct matches the plasmid you designed.

High cytotoxicity

Reduce MOI, reduce or remove polybrene and consider a polybrene-free alternative, and shorten the exposure window before replacing with fresh medium. Compare against a no-virus, enhancer-only mock control to separate viral toxicity from enhancer toxicity.

Selection never clears

Re-run a kill curve on your specific untransduced line at your specific passage — a borrowed antibiotic concentration is a common cause of a selection that never fully clears untransduced controls. Confirm the resistance cassette on the transfer plasmid matches the selection drug in use.

Cells appear positive but show no functional effect (knockdown/knockout/overexpression)

Confirm integration and expression independently (qPCR, western blot, or the relevant functional assay) rather than relying on the fluorescent marker or resistance alone — a functional marker on the same construct does not guarantee the gene of interest itself is expressed or edited as intended.

Frequently asked questions

What is the difference between lentiviral transduction and transfection?

Transduction uses a viral vector — lentivirus here — to deliver genetic material; transfection delivers it by chemical (lipid, calcium phosphate, PEI) or physical (electroporation, microinjection) non-viral means. See the transfection guide for the non-viral methods and the same terminology distinction in more detail. The two are not interchangeable in biosafety terms: viral transduction carries a materially heavier IBC and containment burden than chemical transfection of the same insert.

Why use lentivirus instead of a standard retrovirus?

Because lentivirus can cross an intact nuclear envelope, it transduces non-dividing and slowly dividing cells — primary neurons, macrophages, resting lymphocytes — that a gamma-retroviral vector cannot integrate into, since that vector class requires nuclear envelope breakdown during mitosis.

What MOI should I use?

There is no universal number — it depends on the target cell line, the construct, and whether single-copy integration matters for your application. Run a small titration on your own system rather than inheriting a figure from a paper or vendor protocol; many stable-line workflows deliberately target a low MOI to bias toward single-copy integration.

Do I need IBC approval for lentiviral work?

Generally yes, and approval must be in place before work begins. Recombinant/synthetic nucleic acid research is reviewed by the Institutional Biosafety Committee under the NIH Guidelines at institutions receiving NIH funding, and viral vector work in particular is very unlikely to be exempt from that review.

What biosafety level does lentiviral work require?

Commonly BSL-2, or BSL-2 with enhanced practices depending on the vector generation, pseudotyping, and what the insert encodes — but the specific tier is a risk-assessment determination made by the IBC and biosafety office, not a fixed universal answer.

What does polybrene do in a transduction protocol?

It is a cationic polymer, typically used around 6–8 μg/mL, that neutralizes charge repulsion between the viral envelope and the cell surface to increase effective viral contact and transduction efficiency. Some cell types are sensitive to it and may need a lower concentration or a polybrene-free alternative such as Retronectin-coated plates.